What does Brexit mean for the life sciences sector? A regulatory law perspective

11/12/2018

GO

With just over three months to go before the United Kingdom ceases to be a member of the European Union, companies in the life sciences sector must ensure that they are prepared for the changes and aware of how these may affect their business.

In this Lexology webinar, Bristows’ experts will examine the regulatory law implications of Brexit for the life sciences industry, with a focus on medicinal products, medical devices and product liability. In particular, they will provide insight into the key regulatory law considerations for stakeholders in the life sciences sector, to ensure business continuity and minimise risks after Brexit in both the European Union and the United Kingdom. They will also cover any progress made on the withdrawal agreement and any transitional period implications. At the end of the presentation, they will be available to answer your questions.  

The talk is aimed at in-house counsel in the pharmaceutical, medical devices and health sectors, as well as European, Asian and US lawyers who want to keep up to date with the UK life sciences regulatory landscape.

Sign up via the Lexology website.

Speakers

15:00
15:55

With just over three months to go before the United Kingdom ceases to be a member of the European Union, companies in the life sciences sector must ensure that they are prepared for the changes and aware of how these may affect their business.
Back to Events